Testosterone deficiency and Peyronie's disease: Pilot data suggesting a significant relationship

Journal of Sexual Medicine

Volumn 6, Issue 6, 2009, Pages 1729-1735

  Moreno, Sergio A ^a   Morgentaler, Abraham ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Hypogonadism; Penile curvature; Peyronie's disease; Testosterone

Indexed keywords

PROSTAGLANDIN E1; TESTOSTERONE;

ADULT; AGED; ANDROGEN DEFICIENCY; ARTICLE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PAIN; PENIS INJURY; PEYRONIE DISEASE; PHYSICAL EXAMINATION; PILOT STUDY; PREVALENCE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL;

EID: 66649093844     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01250.x     Document Type: Article

References (48)

1. Taylor FL, Levine LA. Peyronie's disease. Urol Clin North Am 2007;34:517-34.
2. Jordan GH. Peyronie's disease. In: Wein AJ, ed. Wein: Campbell-Walsh urology. 9th edition. St. Louis, MO: Saunders; 2007:818-38.
3. Gholami SS, Gonzalez-Cadavid NF, Lin CS, Rajfer J, Lue TF. Peyronie's disease: A review. J Urol 2003;169:1234-41.
4. Moreland RB, Nehra A. Pathophysiology of Peyronie's disease. Int J Impot Res 2002;14:406-10.
5. Gonzalez-Cadavid NF, Magee TR, Ferrini M, Qian A, Vernet D, Rajfer J. Gene expression in Peyronie's disease. Int J Impot Res 2002;14:361-74.
6. Devine CJ Jr, Somers KD, Jordan GH, Schlossberg SM. Proposal: Trauma as the cause of the Peyronie's lesion. J Urol 1997;157:285-90.
7. Jarow JP, Lowe FC. Penile trauma: An etiologic factor in Peyronie's disease and erectile dysfunction. J Urol 1997;158:1388-90.
8. Somers KD, Dawson DM. Fibrin deposition in Peyronie's disease plaque. J Urol 1997;157: 311-5.
9. Davis CJ Jr. The microscopic pathology of Peyronie's disease. J Urol 1997;157:282-4.
10. Ehrlich HP. Scar contracture: Cellular and connective tissue aspects in Peyronie's disease. J Urol 1997;157:316-9.
11. Lyles KW, Gold DT, Newton RA, Parekh S, Shipp KM, Pieper CF, Krishan R, Carson CC 3rd. Peyronie's disease is associated with Paget's disease of the bone. J Bone Miner Res 1997;12:929-34.
12. Nyberg LM, Bias WB, Hochberg MC, Walsh PC. Identification of an inherited form of Peyronie's disease with an autosomal dominant inheritance and association with Dupuytren's contracture and histocompatability B7 cross-reactive antigens. J Urol 1982;128:48-51.
13. Ralph DJ, Schwartz G, Moore W, Pryor JP, Ebringer A, Bottazzo GF. The genetic and bacteriological aspects of Peyronie's disease. J Urol 1997;157:291-4.
14. Noss MB, Day NS, Christ GJ, Melman A. The genetics and immunology of Peyronie's disease. Int J Impot Res 2000;4 (suppl):S127-32.
15. Qian A, Meals RA, Rajfer J, Gonzalez-Cadavid NF. Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology 2004;64:399-404.
16. Schiavino D, Sasso F, Nucera E, Alcini E, Gulino G, Milani A, Patriarca G. Immunologic findings in Peyronie's disease: A controlled study. Urology 1997;50:764-8.
17. Stewart S, Malto M, Sandberg L, Colburn KK. Increased serum levels of anti-elastin antibodies in patients with Peyronie's disease. J Urol 1994;152:105-6.
18. Leffell MS. Is there an immunogenetic basis for Peyronie's disease? J Urol 1997;157:295-7.
19. Sommer F, Schwarzer U, Wassmer G, Bloch W, Braun M, Klotz T, Engelmann U. Epidemiology of Peyronie's disease. Int J Impot Res 2002;14:379-83.
20. Lindsay MB, Schain DM, Grambsch P, Benson RC, Beard CM, Kurkland LT. The incidence of Peyronie's disease in Rochester, Minnesota, 1950 through 1984. J Urol 1991;146:1007-9.
21. Demling RH. The role of anabolic hormones for wound healing in catabolic states. J Burns Wounds 2005;4:46-62.
22. Hetzler LE, Sharma N, Tanzer L, Wurster RD, Leonetti J, Marzo SJ, Jones KJ, Foecking EM. Accelerating functional recovery after rat facial nerve injury: Effects of gonadal steroids and electrical stimulation. Otolaryngol Head Neck Surg 2008;139:62-7.
23. Maus U, Andereya S, Schmidt H, Zombory G, Gravius S, Ohnsorge JA, Niedhart C. Therapy effects of testosterone on the recovery of bone defects. Z Orthop Unfall 2008;146: 59-63.
24. Wu FCW, Tajar A, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M, Boonen S, Vanderschueren D, The European Male Aging Study Group. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: The European Male Aging Study. J Clin Endocrinol Metab 2008;93:2737-45.
25. Corona G, Mannucci E, Fisher AD, Lotti F, Petrone L, Balercia G, Bandini E, Forti G, Maggi M. Low levels of androgens in men with erectile dysfunction and obesity. J Sex Med 2008;5:2454-63.
26. Bashin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2006;91:1995-2010.
27. Morgentaler A. Commentary: Guideline for male testosterone therapy: A clinician's perspective. J Clin Endocrinol Metab 2007;92:416-7.
28. El-Sakka AI. Prevalence of Peyronie's disease among patients with erectile dysfunction. Eur Urol 2006;49:564-9.
29. Usta MF, Bivalacqua TJ, Jabren GW, Myers L, Sanabria J, Sikka SC, Hellstrom WJG. Relationship between the severity of penile curvature and the presence of comorbidities in men with Peyronie's disease. J Urol 2004;171:775-9.
30. Carrieri MP, Serraino D, Palmiotto F, Nucci G, Sasso F. A case-control study on risk factors for Peyronie's disease. J Clin Epidemiol 1998;51:511-5.
31. Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S. A retrospective review of 307 men with Peyronie's disease. J Urol 2002;168:1075-9.
32. La Pera G, Pescatori ES, Calabrese M, Boffini A, Colombo F, Andriani E, Natali A, Vaggi L, Catuogno C, Giustini M, Taggi F, SIMONA Study Group. Peyronie's disease prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50-69 years. Eur Urol 2001;40:525-30.
33. Rhoden EL, Buselato LG, Ting HY, Teloken C, Souto CA. Is there any association between Peyronie's disease and serum collagen markers? Int J Impot Res 2002;14:167-71.
34. Morgentaler A. Testosterone and sexual function. Med Clin North Am 2006;90(1 suppl):32-4.
35. Traish AM, Park K, Dhir V, Kimm NN, Moreland RB, Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999;140:1861-8.
36. Traish A, Kim N. Weapons of penile smooth muscle destruction: Androgen deficiency promotes accumulation of adipocytes in the corpus cavernosum. Aging Male 2005;8:141-6.
37. Traish A, Toselli P, Jeong SJ, Kim NN. Adipocyte accumulation in penile corpus cavernosum of the orchiectomized rabbit: A potential mechanism for veno-occlusive dysfunction in androgen deficiency. J Androl 2005;26:242-8.
38. Yassin AA, Saad F. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. J Sex Med 2007;4:497-501.
39. Kwan M, Greenleaf WJ, Mann J, Crapo L, Davison JM. The nature of androgen action on male sexuality: A combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Metab 1983;57:557-62.
40. Reyes-Vallejo L, Lazarou S, Morgentaler A. Subjective sexual response to testosterone replacement therapy based on initial serum levels of testosterone. J Sexual Med 2007;4:1757-62.
41. Arver S, Dobs AS, Meikle AW, Allen RP, Sanders SW, Mazer NA. Improvement of sexual function in testosterone deficient men treated for 1 year with permeation enhanced testosterone transdermal system. J Urol 1996;155:1604-8.
42. Gonzalez-Cadavid NF, Ignarro LJ, Rajfer J. Nitric oxide and cyclic GMP system in the penis. Mol Urol 1999;3:51-9.
43. Burnett AL. Nitric oxide in the penis: Physiology and pathology. J Urol 1997;157:320-4.
44. Mills TM, Wiedmeier VT, Stopper VS. Androgen maintenance of erectile function in the rat penis. Biol Reprod 1992;46:342-8.
45. Reilly CM, Zamorano P, Stopper VS, Mills TM. Androgenic regulation of NO availability in rat penis erection. J Androl 1997;18:110-5.
46. Lugg JA, Rajfer J, Gonzalez-Cadavid NF. Dihydrotestosterone is the active androgen in the maintenance of nitric oxide-mediated penile erection in the rat. Endocrinology 1995;136:1495-501.
47. Seftel AD. The positive trophic effects of testosterone on neuronal nitric oxide synthase (nNOS) expression. J Androl 1997;18:745.
48. Zvara P, Sioufi R, Schipper HM, Begin LR, Brock GB. Nitric oxide mediated erectile activity is a testosterone dependent event: A rat erection model. Int J Impot Res 1995;7:209-19.